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The US Food and Drug Administration (FDA) notified Congress July 31, 2014,1 of its intent 
to regulate laboratory developed tests. These encompass thousands of clinical assays 
currently used in medical practice including most pharmacogenetic tests. This guidance has 
the potential to impact the innovation and sustainability of pharmacogenetic research and its 
clinical implementation.
We anticipate that several requirements could have substantial implications for both clinical 
research and the clinical implementation of pharmacogenetics. Input from federal funding 
agencies (eg, National Institutes of Health, Agency for Health Research Quality, Patient-
Centered Outcomes Research Institute) will be needed to clarify who will bear the financial 
burden of some of the increased requirements. Further, key clarifications will be required 
from the FDA to understand how implementation will occur over the next decade (Figure 1). 
Clarity now will allow the research and clinical communities to effectively plan and budget 
for these changes. Below, we identify and describe the key issues.
Over the past decades, many pharmacogenomics biomarkers that are responsible for clinical 
variability in the pharmacokinetics and pharmacodynamics of drug therapy have been 
identified. These studies have mostly been conducted using laboratory-developed 
procedures or tests (LDTs).2 According to the published guidance, it appears that these 
clinical discovery and validation studies will now need to obtain investigational device 
exemptions (IDEs) from the FDA. For example, conducting a simple clinical study to 
determine if genetic variants in a drug-metabolizing enzyme are associated with the 
pharmacokinetics of a drug would require that the genotyping assay laboratory obtain an 
IDE before conducting the study. IDE submissions require substantial expertise and 
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resources that are not typically common in academic research centers or Clinical Laboratory 
Improvement Amendment (CLIA)–certified clinical laboratories. This may even be new for 
drug companies that may have expertise in new drug application submissions, but not IDEs. 
Therefore, it will substantially increase the cost and resources needed to conduct these 
studies. It is not clear to us what harm has been done that will be solved by the IDE 
requirement that justifies such a change. The question of funding is important. Will funding 
agencies be willing to support these additional costs, or will it just reduce the scope or 
number of studies that will be able to be conducted? We suggest that the FDA use its 
enforcement discretion and not require IDEs for these types of translational studies.
Based on the language in the guidance document, clinical (ie, CLIA) laboratories providing 
pharmacogenetic genotyping using an LDT will be required to obtain premarket approvals 
(PMAs). As there are very few FDA-approved pharmacogenetic in vitro diagnostic devices, 
most clinical testing using LDTs is performed in CLIA laboratories, often with College of 
American Pathologists accreditation. The time and costs involved in obtaining PMAs are 
high. In a 2010 survey and analysis conducted by AdvaMed,3 US patients waited an average 
of 2 years longer than those in Europe to gain access to new medical technologies, which 
was attributable to the FDA device approval. In addition, the average total cost to bring a 
low to moderate in vitro diagnostic through the FDA 510(k) process was $31 million, with 
$24 million spent on FDA-dependent or -related activities. For higher-risk products 
submitted for approval, the average cost increased to $94 million, with $75 million linked to 
FDA requirements. In addition, the industry reported an average time from first 
communication with the FDA to clearance or approval ranging from 31 to 54 months. The 
FDA claims that CLIA certification of a laboratory performing an LDT does not provide the 
safety, oversight, and adverse event reporting requirements that exist with devices cleared or 
approved by the agency; however, this has not been supported by statistically valid evidence 
that this has caused harm to patients. At least publicly, they have only cited antidotal cases 
where a patient received inappropriate therapy as a result of a faulty LDT. In the FDA's 
notice to Congress of its intent to initiate oversight of LDTs (Federal Register/Vol. 79, No. 
192/Friday, October 3, 2014), there was no data submitted that supports the claim that the 
status quo condition was causing harm. Despite this lack of evidence, it does express a 
concern about the potential risk to patients if LDTs do not receive oversight. The FDA in 
their October 2014 filing in the Federal Register noted that the complexity and expanded use 
of LDTs today are significantly different from 1976 when the Congress enacted Medical 
Device Amendment (MDA) and expanded the FDA oversight of medical devices intended 
for human use. To support the oversight of LDTs, the FDA is using the 1976 MDA in 
attempt to redefine laboratories that perform LDTs as manufacturers of medical devices 
intended for human use. There are potentially many implications, including financial and 
health economics, if the FDA is allowed to categorize these laboratories as manufacturers. 
During the September 9, 2014 House Committee on Energy and Commerce Hearing on the 
Proposed FDA Laboratory Developed Test Policy, Dr. Jeff Shuren, the Director of the 
Center for Devices and Radiological Health at the FDA, stated that the “FDA has not 
conducted a formal economic analysis” to justify the increased time and cost required to 
implement the proposed framework. In this context, it would be valuable to consider a “fast 
track” approval process or other creative approaches for new tests that have evidence of life-
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saving benefits (i.e., HLA-B*57:01 and abacavir), in the same way as drugs has occurred for 
drug approvals.
Currently, many laboratories decide on a genotyping platform that fits the needs of their 
laboratory and then design LDTs for multiple assays on a single platform. However, with 
companion diagnostics in which the drug and device are approved together by the FDA, 
drug and device manufacturers essentially have 1 instrument per drug, making it necessary 
for the laboratories to obtain multiple different instruments to provide pharmacogenomic 
services for multiple drugs. The initial capital investment and routine running costs (eg, 
maintenance contracts, training, and competency) will thus be much higher for laboratories. 
Depending on the device labeling, it could even require different instruments for the same 
genetic test when used for different drugs (eg, CYP2D6 testing for codeine and 
antidepressants), even though they test the exact same genetic variants. If the device (ie, 
instrument and test kit) is used for a different intended use (ie, same gene, different drug), 
then the laboratory will need to submit to the FDA to demonstrate cross-platform 
equivalency.
Last, input from payers will be needed to understand how reimbursement for clinical testing 
will be handled. For example, once a test is FDA-approved or -cleared, will the payers 
reimburse those tests at a significantly higher rate, so the clinical laboratory can recoup its 
cost for the FDA submission? The current procedural terminology coding system for 
reimbursement is platform agnostic. Though Centers for Medicare and Medicaid Service has 
a pilot program to differentiate reimbursement based on platform,4 will the payers even 
allow reimbursement for non-FDA-approved tests when there are FDA-approved tests 
available?
In conclusion, many questions remain to be answered related to the new FDA guidance on 
LDTs with respect to clinical research and implementation of pharmacogenetic testing. The 
FDA should provide specific evidence about the harm caused by LDTs, so a less obstructive 
solution could be identified. Although it may be true that there are some CLIA-accredited 
laboratories that have developed their own methods and tests that do not meet acceptable 
quality standards, why not selectively pursue these entities through existing or enhanced 
CLIA regulations rather than imposing FDA-directed oppressive and costly guidance across 
the entire spectrum of laboratory service providers and researchers?
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Figure 1. 
FDA timeline for implementation of oversight of laboratory-developed tests. *Time from 
FDA comment review and congressional input to the release of the final guidance is 
unknown. **PMA process is based on a per se demonstration of safety and effectiveness 
through “adequate and well-controlled” clinical trials. A successful PMA submission results 
in approval of the new device. The 510(k) process is somewhat analogous to the “generic” 
drug concept in that Premarket Notification is used to obtain marketing clearance for a 
device that is “substantially equivalent” in safety and effectiveness to another lawfully 
marketed device or to a standard recognized by the FDA when used for the same intended 
purpose(s).1 Federal regulations include medical device reporting as defined in the Code of 
Federal Register (CFR §803) and implementation of quality systems regulation (21 CFR 
§820).
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